Angela Lopedota1, Annalisa Cutrignelli2, Valentino Laquintana2, Nunzio Denora2, Rosa Maria Iacobazzi2,3, Mara Perrone2, Elisabetta Fanizza4,5, Maria Mastrodonato6, Donatella Mentino6, Antonio Lopalco7, Nicoletta Depalo5, Massimo Franco2. 1. Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 4 Orabona Street, 70125, Bari, Italy. angelaassunta.lopedota@uniba.it. 2. Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 4 Orabona Street, 70125, Bari, Italy. 3. Istituto Tumori IRCCS Giovanni Paolo II, Bari, Italy. 4. Department of Chemistry, University of Bari "Aldo Moro", Bari, Italy. 5. CNR-Institute for Physical and Chemical Processes UOS, Bari, Italy. 6. Department of Biology, Section of Animal and Environmental Biology, University of Bari "Aldo Moro", Bari, Italy. 7. Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, USA.
Abstract
PURPOSE: Chitosan microparticles containing celecoxib (CB), were developed as chemoprevention of bladder cancer. Furthermore two inclusion complexes of CB with methyl-β-cyclodextrin (C1 and C2) were prepared to improve the solubility of the drug. METHODS: C1 and C2 were obtained by freeze-drying and characterized in the solid state and in solution. Microparticles loaded with CB or C1 or C2 were prepared by spray drying and fully characterized. RESULTS: The yield and encapsulation efficiencies of microparticles depended by both the viscosity and the presence of the inclusion complex in the feed medium nebulised. Generally, the microparticles exhibited a spherical shape with mean diameter of approximately 2 μm which was compatible with local intravesical administration using a catheter. The CB release studies from the microparticles allowed us to identify both immediate release systems (microparticles including the complexes) and prolonged release systems (microparticles including CB alone). The latter exhibited good adhesion to the bladder mucosa, as highlighted by a mucoadhesion study. Histological studies revealed a desquamation of the superficial cells when the bladder mucosa was treated with microparticles loaded with CB, while the morphology of the urothelium did not change when it was treated with microparticles loaded with the inclusion complex. CONCLUSION: A new CB intravesical formulation than can easily be administered with a catheter and is able to release the drug at the target site for several hours was realized. This new delivery system could be a good alternative to classic oral CB administration.
PURPOSE: Chitosan microparticles containing celecoxib (CB), were developed as chemoprevention of bladder cancer. Furthermore two inclusion complexes of CB with methyl-β-cyclodextrin (C1 and C2) were prepared to improve the solubility of the drug. METHODS:C1 and C2 were obtained by freeze-drying and characterized in the solid state and in solution. Microparticles loaded with CB or C1 or C2 were prepared by spray drying and fully characterized. RESULTS: The yield and encapsulation efficiencies of microparticles depended by both the viscosity and the presence of the inclusion complex in the feed medium nebulised. Generally, the microparticles exhibited a spherical shape with mean diameter of approximately 2 μm which was compatible with local intravesical administration using a catheter. The CB release studies from the microparticles allowed us to identify both immediate release systems (microparticles including the complexes) and prolonged release systems (microparticles including CB alone). The latter exhibited good adhesion to the bladder mucosa, as highlighted by a mucoadhesion study. Histological studies revealed a desquamation of the superficial cells when the bladder mucosa was treated with microparticles loaded with CB, while the morphology of the urothelium did not change when it was treated with microparticles loaded with the inclusion complex. CONCLUSION: A new CB intravesical formulation than can easily be administered with a catheter and is able to release the drug at the target site for several hours was realized. This new delivery system could be a good alternative to classic oral CB administration.
Authors: Mirna Fernández Cervera; Jyrki Heinämäki; Nilia de la Paz; Orestes López; Sirkka Liisa Maunu; Tommi Virtanen; Timo Hatanpää; Osmo Antikainen; Antonio Nogueira; Jorge Fundora; Jouko Yliruusi Journal: AAPS PharmSciTech Date: 2011-05-11 Impact factor: 3.246
Authors: Claudia G Fresta; Aishik Chakraborty; Manjula B Wijesinghe; Angela M Amorini; Giacomo Lazzarino; Giuseppe Lazzarino; Barbara Tavazzi; Susan M Lunte; Filippo Caraci; Prajnaparamita Dhar; Giuseppe Caruso Journal: Cell Death Dis Date: 2018-02-14 Impact factor: 8.469
Authors: Giuseppe Caruso; Claudia G Fresta; Angelita Costantino; Giacomo Lazzarino; Angela M Amorini; Giuseppe Lazzarino; Barbara Tavazzi; Susan M Lunte; Prajnaparamita Dhar; Massimo Gulisano; Filippo Caraci Journal: Int J Mol Sci Date: 2021-03-07 Impact factor: 5.923